Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02632045
Title Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer (MAINTAIN)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Kevin Kalinsky
Indications

Her2-receptor negative breast cancer

Therapies

Fulvestrant + Ribociclib

Fulvestrant

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.